Pfizer (PFE) said it is optimistic lyme disease vaccine will get registration after 70%-plus efficacy data; says it continues to beat the expectations for revenue or EPS in '24, '25, and Q1 '26
- China is becoming a "scientific superpower" and its future competition may be Chinese mega players rather than Eli Lilly (LLY) or AstraZeneca (AZN LN) in five years.
#PFIZER INC#PFE.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES